Krystal Biotech earnings were $241.5M for the trailing 12 months ending Jun 30, 2026, with 61.8% growth year over year. The latest KRYS earnings report on Jun 30, 2026 announced Q2 2026 earnings of $54.8M, down 2.1% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, KRYS reported annual earnings of $204.8M, with 129.7% growth.
KRYS past earnings growth
How has KRYS's earnings growth performed historically?
What were Krystal Biotech's earnings last quarter?
On KRYS's earnings call on Aug 3, 2026, Krystal Biotech (NASDAQ: KRYS) reported Q2 2026 earnings per share (EPS) of $1.85, up 39.1% year over year. Total KRYS earnings for the quarter were $54.77 million. In the same quarter last year, Krystal Biotech's earnings per share (EPS) was $1.33.
As of the last Krystal Biotech earnings report, Krystal Biotech is currently profitable. Krystal Biotech's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $241.47 million, a 64.57% increase year over year.
What was KRYS's earnings growth in the past year?
As of Krystal Biotech's earnings date in Aug 3, 2026, Krystal Biotech's earnings has grown 61.84% year over year. This is 19.74 percentage points higher than the US Biotechnology industry earnings growth rate of 42.1%. KRYS earnings in the past year totalled $241.47 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.